Log in with your email address username.

×

Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Comment] J-ALEX: alectinib versus crizotinib in ALK-positive lung cancer

Notable insights into the genetic landscape of non-small-cell lung cancer have helped drive improvements in the management of advanced disease. Although traditional treatments tend to be anchored solely in cytotoxic chemotherapy, more recent strategies incorporate targeted therapies for some patients. Anaplastic lymphoma kinase (ALK) rearrangements are one of the earliest validated molecular targets in non-small-cell lung cancer. Standard first-line therapy for advanced, ALK-positive non-small-cell lung cancer is the multitargeted ALK/ROS1/MET inhibitor, crizotinib,1,2 followed by more potent second-generation ALK inhibitors, like ceritinib or alectinib, upon progression.

email